TWI800759B - 醫藥劑型 - Google Patents

醫藥劑型 Download PDF

Info

Publication number
TWI800759B
TWI800759B TW109136485A TW109136485A TWI800759B TW I800759 B TWI800759 B TW I800759B TW 109136485 A TW109136485 A TW 109136485A TW 109136485 A TW109136485 A TW 109136485A TW I800759 B TWI800759 B TW I800759B
Authority
TW
Taiwan
Prior art keywords
dosage forms
pharmaceutical dosage
pharmaceutical
forms
dosage
Prior art date
Application number
TW109136485A
Other languages
English (en)
Other versions
TW202128137A (zh
Inventor
蘇西 瑞貝洛
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202128137A publication Critical patent/TW202128137A/zh
Application granted granted Critical
Publication of TWI800759B publication Critical patent/TWI800759B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW109136485A 2013-12-13 2014-12-12 醫藥劑型 TWI800759B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915606P 2013-12-13 2013-12-13
US61/915,606 2013-12-13

Publications (2)

Publication Number Publication Date
TW202128137A TW202128137A (zh) 2021-08-01
TWI800759B true TWI800759B (zh) 2023-05-01

Family

ID=52146563

Family Applications (2)

Application Number Title Priority Date Filing Date
TW103143546A TWI721938B (zh) 2013-12-13 2014-12-12 醫藥劑型
TW109136485A TWI800759B (zh) 2013-12-13 2014-12-12 醫藥劑型

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW103143546A TWI721938B (zh) 2013-12-13 2014-12-12 醫藥劑型

Country Status (34)

Country Link
US (3) US10278969B2 (zh)
EP (2) EP3079667B1 (zh)
JP (2) JP6522619B2 (zh)
KR (1) KR102349893B1 (zh)
CN (2) CN105813635A (zh)
AR (1) AR098716A1 (zh)
AU (1) AU2014362999B2 (zh)
CA (1) CA2930055C (zh)
CL (1) CL2016001436A1 (zh)
CY (1) CY1122063T1 (zh)
DK (1) DK3079667T3 (zh)
EA (1) EA036288B1 (zh)
EC (1) ECSP16060194A (zh)
ES (1) ES2745983T3 (zh)
HK (1) HK1223833A1 (zh)
HR (1) HRP20191691T1 (zh)
HU (1) HUE045156T2 (zh)
IL (1) IL245705B (zh)
LT (1) LT3079667T (zh)
MA (1) MA39175A1 (zh)
MX (1) MX2016007652A (zh)
MY (1) MY194303A (zh)
NZ (2) NZ719865A (zh)
PE (1) PE20160851A1 (zh)
PH (1) PH12016501039A1 (zh)
PL (1) PL3079667T3 (zh)
PT (1) PT3079667T (zh)
RS (1) RS59270B1 (zh)
SG (1) SG10202104627UA (zh)
SI (1) SI3079667T1 (zh)
TN (1) TN2016000207A1 (zh)
TW (2) TWI721938B (zh)
WO (1) WO2015087283A1 (zh)
ZA (1) ZA201603064B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
CA3202267A1 (en) * 2020-12-18 2022-06-23 Riccardo Panicucci Methods of treating achondroplasia
KR20230156952A (ko) * 2021-03-17 2023-11-15 액테리온 파마슈티칼 리미티드 약제 투여 시스템

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035769A (zh) * 2004-06-24 2007-09-12 诺瓦提斯公司 作为激酶抑制剂的嘧啶脲衍生物
CN102639510A (zh) * 2009-12-07 2012-08-15 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲及其盐的晶型

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591443A (en) 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007071752A2 (en) 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
AU2012279301A1 (en) 2011-07-01 2014-01-09 Novartis Ag Combination therapy
AU2014287209B2 (en) 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
AU2014362999B2 (en) 2013-12-13 2017-10-12 Novartis Ag Pharmaceutical dosage forms
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
EP3273959A1 (en) 2015-03-25 2018-01-31 Novartis Ag Pharmaceutical combinations
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035769A (zh) * 2004-06-24 2007-09-12 诺瓦提斯公司 作为激酶抑制剂的嘧啶脲衍生物
CN102639510A (zh) * 2009-12-07 2012-08-15 诺瓦提斯公司 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲及其盐的晶型

Also Published As

Publication number Publication date
CY1122063T1 (el) 2020-11-25
PT3079667T (pt) 2019-10-10
AR098716A1 (es) 2016-06-08
KR102349893B1 (ko) 2022-01-10
IL245705A0 (en) 2016-07-31
ECSP16060194A (es) 2019-07-31
PE20160851A1 (es) 2016-09-14
US20200054632A1 (en) 2020-02-20
SG10202104627UA (en) 2021-06-29
HRP20191691T1 (hr) 2019-12-27
KR20160096093A (ko) 2016-08-12
US10278969B2 (en) 2019-05-07
TWI721938B (zh) 2021-03-21
MX2016007652A (es) 2016-10-13
CN105813635A (zh) 2016-07-27
MY194303A (en) 2022-11-27
NZ760002A (en) 2022-07-29
SI3079667T1 (sl) 2019-10-30
JP6804585B2 (ja) 2020-12-23
EA036288B1 (ru) 2020-10-22
IL245705B (en) 2021-05-31
WO2015087283A1 (en) 2015-06-18
JP2017502941A (ja) 2017-01-26
AU2014362999B2 (en) 2017-10-12
HUE045156T2 (hu) 2019-12-30
CA2930055A1 (en) 2015-06-18
CL2016001436A1 (es) 2017-02-10
CA2930055C (en) 2023-07-04
DK3079667T3 (da) 2019-09-09
US11160804B2 (en) 2021-11-02
AU2014362999A1 (en) 2016-05-26
HK1223833A1 (zh) 2017-08-11
TW202128137A (zh) 2021-08-01
PH12016501039A1 (en) 2016-07-04
JP2019142927A (ja) 2019-08-29
TW201605494A (zh) 2016-02-16
EP3597179A1 (en) 2020-01-22
MA39175A1 (fr) 2017-10-31
RS59270B1 (sr) 2019-10-31
ZA201603064B (en) 2017-07-26
TN2016000207A1 (en) 2017-10-06
JP6522619B2 (ja) 2019-05-29
US20220265651A1 (en) 2022-08-25
LT3079667T (lt) 2019-09-10
ES2745983T3 (es) 2020-03-04
US20170007602A1 (en) 2017-01-12
PL3079667T3 (pl) 2020-02-28
EP3079667A1 (en) 2016-10-19
CN116942629A (zh) 2023-10-27
EP3597179B1 (en) 2024-04-03
EP3079667B1 (en) 2019-06-26
EA201691231A1 (ru) 2016-10-31
NZ719865A (en) 2022-07-29

Similar Documents

Publication Publication Date Title
GB201322602D0 (en) Pharmaceutical compounds
GB201306610D0 (en) Pharmaceutical compounds
ZA201602047B (en) Pharmaceutical compounds
ZA201507576B (en) Pharmaceutical combination drug
EP3003324A4 (en) Pharmaceutical compositions
HK1223833A1 (zh) 藥物劑型
GB201318686D0 (en) Pharmaceutical preparations
ZA201600027B (en) Pharmaceutical preparation
GB201301721D0 (en) Pharmaceutical Preparations
GB201312386D0 (en) Pharmaceutical compounds
EP2992890A4 (en) Pharmaceutical composition
ZA201506465B (en) Pharmaceutical preparation
EP3052475A4 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile
AU2013903813A0 (en) Pharmaceutical composition
GB201317166D0 (en) Pharmaceutical compounds
GB201316791D0 (en) Pharmaceutical Compounds
GB201316780D0 (en) Pharmaceutical compounds
GB201315734D0 (en) Pharmaceutical compounds
GB201315733D0 (en) Pharmaceutical compounds
GB201312464D0 (en) Pharmaceutical compounds
GB201308782D0 (en) Pharmaceutical compounds
GB201308781D0 (en) Pharmaceutical compounds
GB201308780D0 (en) Pharmaceutical compounds
GB201316662D0 (en) Pharmaceutical Combination
AU2013902265A0 (en) Dose Calculation